Catalent (Catalent) LT-Debt-to-Total-Asset : 0.50 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Catalent LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Catalent's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.50.

Catalent's long-term debt to total assets ratio increased from Dec. 2022 (0.38) to Dec. 2023 (0.50). It may suggest that Catalent is progressively becoming more dependent on debt to grow their business.

Catalent LT-Debt-to-Total-Asset Historical Data

The historical data trend for Catalent's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalent LT-Debt-to-Total-Asset Chart

Catalent Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.47

0.38

0.35

0.40

Catalent Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.38	0.39	0.40	0.43	0.50

Catalent LT-Debt-to-Total-Asset Calculation

Catalent's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

LT Debt to Total Assets (A: Jun. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Jun. 2023 )	/	Total Assets (A: Jun. 2023 )
	=	4313	/	10777
	=	0.40

Catalent's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	4959	/	9988
	=	0.50

Catalent (NYSE:CTLT) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Catalent LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Catalent's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Catalent (Catalent) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Catalent Inc (NYSE:CTLT) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

0C8:Germany 0C8:Germany

Address

14 Schoolhouse Road, Somerset, NJ, USA, 08873

Website

https://www.catalent.com

Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.

Executives

David Mcerlane	officer: Group President, Biologics	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Steven Barg	director	ELLIOTT MANAGEMENT CORPORATION, 40 WEST 57TH STREET, NEW YORK NY 10019
Michelle R Ryan	director	214 PARK BLVD S, VENICE FL 34285
John J Greisch	director	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Stephanie Okey	director	C/O ALBIREO PHARMA, INC., 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON MA 02109
Frank A Damelio	director	C/O PFIZER INC., 235 EAST 42ND ST., NEW YORK NY 10017
Aristippos Gennadios	officer: See Remarks	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Thomas W Hawkeswood	officer: Pres. Pharma Prod Delivery Div	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Patricia Hunt	officer: Pres. Consumer Health Div	C/O CATALENT, 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Ricky Hopson	officer: VP, Chief Accounting Officer	CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Lorenzo Carletti	officer: SVP Global Ops Small Molecule	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Ricardo Pravda	officer: SVP, Human Resources	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Alessandro Maselli	officer: See remarks	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Charles Lickfold	officer: SVP, CIO	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Scott Gunther	officer: See Remarks	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873